Large Volume Wearable Injectors Market (4th Edition), 2018-2030

  • ID: 4746719
  • Report
  • Region: Global
  • 348 Pages
  • Roots Analysis
1 of 5
The Market for Large Volume Wearable Injectors is Anticipated to Reach Over USD 1.5 Billion by 2030, Representing a CAGR of Close to 5%

FEATURED COMPANIES

  • 3M
  • Battelle
  • EG-GILERO
  • Innate Pharma
  • Neon Therapeutics
  • Sanofi
  • MORE

Chronic clinical conditions, such as diabetes, cardiovascular disorders, neurological disorders, autoimmune disorders and various types of cancer, are considered to be among the leading causes of death and disability across the world. Recently, the Center for Managing Chronic Disease at the University of Michigan reported that over 50% of the global population is currently suffering from some form of chronic disease. The past few years have witnessed groundbreaking advances in the process of drug development and the introduction of several innovative pharmaceutical interventions for the treatment of a number of chronic diseases. However, the majority of the available treatment options require parenteral administration, frequent dosing, involve repeated hospital visits and are associated with multiple other concerns, such as dosing and medication errors, the risk of microbial contamination and needlestick injuries. These challenges represent a substantial threat to medication adherence and, thereby, are likely to significantly impact therapeutic outcomes. Over the past few years, a number of companies have developed advanced therapeutic delivery solutions to alleviate the pressing concerns associated with the administration of both conventional and novel drug/therapy molecules. Amongst modern drug delivery practices, the concept of self-injection has facilitated advanced medications to be administered beyond the clinical setting. This has also served to reduce healthcare costs, improve therapy adherence and optimize the utilization of healthcare resources per treatment.

The self-injection devices market is currently characterized by the presence of a myriad of advanced and innovative drug delivery solutions, equipped with a variety of user-friendly features. Notable examples of such products include prefilled syringes, reusable and disposable pen injectors, autoinjectors and large volume wearable injectors. Large volume wearable injectors are capable of drug delivery primarily via the subcutaneous route and have become a preferred choice for the administration of drugs in the home-care setting. Variants of these wearable devices have been designed to administer highly viscous drugs (such as most biologics) in large volumes (more than 1 ml), offering numerous benefits, such as ease-of-use, reduced chances of dosing-related errors, integrated safety mechanisms, and almost negligible risk of needlestick injuries. It is worth highlighting that such devices have captured the interest of several stakeholders in this industry to deliver various insulin and non-insulin drugs. Moreover, the field is witnessing emergence of other technological advancements, such as integrated mobile applications with smart health monitoring and other interesting features (such as provisions for reminders, and the ability to connect to web-based portals for sharing medical data with the concerned healthcare providers), visual / audible drug delivery confirmation notifications, automatic drug reconstitution, and error alerts.

The “Large Volume Wearable Injectors Market (4th Edition), 2018-2030” report features an extensive study of the current market landscape and the likely future evolution of self-injection devices, over the next twelve years. It specifically lays emphasis on the emergence of patient-centric, convenient, cost-effective and user-friendly wearable drug delivery solutions that are capable of administering large volumes of a drug subcutaneously, in the home-care setting.

Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the large volume wearable injectors market, highlighting the contributions of industry players related to the delivery of both insulin and non-insulin drugs, along with key device specifications. It features information on current development status of various products (under development and commercialized), type of device (patch pump / injector and infusion pump / injector), type of dose administered (continuous and bolus), route of administration (subcutaneous and others), usability (disposable and reusable), mechanism of action (driving force), mode of injection (needle, needle / cannula and needle / catheter), maximum volume of the device and availability of connected mobile application.
  • A comprehensive product competitiveness analysis of all large volume wearable injectors that we came across, taking into consideration the supplier power (based on the year of establishment) and product specifications, such as type of device, type of dose, maximum volume of the device, usability, allowed route of administration, connectivity with the mobile application and availability of an integrated continuous glucose monitoring / blood glucose monitoring (CGM / BGM) system in case of insulin devices.
  • Elaborate profiles of prominent product developers engaged in this domain, featuring a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and a comprehensive future outlook. Additionally, the report includes tabulated profiles of wearable drug-device combination products.
  • An in-depth analysis of the various patents that have been submitted/filed related to large volume wearable injectors, since 1984. It also highlights the key parameters associated with the patents, including information on the patent type, patent offices, CPC classification, emerging areas (in terms of a number of patents filed/granted) and leading industry players (in terms of the size of intellectual property portfolio).
  • A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors, as observed on the social media platform, Twitter. The analysis was based on tweets posted on the platform from 2013 to 2018 (till September).
  • A comprehensive clinical trial analysis of completed, ongoing and planned studies of various large-volume wearable injector products. For the purpose of this analysis, we considered the clinical studies that started in 2010, and analyzed them on the basis of various parameters, such as trial start year, current trail status, current trial phase, study design, targeted therapeutic area, study focus and clinical outcomes.
  • A case study on the role of contract manufacturing organizations in the overall manufacturing process/supply chain of wearable injectors. It includes short descriptions of the manufacturing services provided by contract service providers in the making of various device components (primary containers), infusion sets, adhesives, closures, and injection moldings.
  • A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future, based on an in-depth analysis of potential candidates, taking into consideration multiple parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs).

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for large volume wearable injectors. Based on parameters, such as the number of commercialized devices, number of devices under development, the price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2018-2030. The report also features sales forecasts for the overall large volume wearable injectors market with a detailed market segmentation on the therapeutic area, geographical distribution of the market (North America / Europe / Asia Pacific / RoW), type of device (patch pump / injector and infusion pump / injector) and usability (reusable / disposable). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base, and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (alphabetical order of companies):

  • Menachem Zucker (VP and Chief Scientist, Elcam Medical)
  • Michael Hooven (CEO, Enable Injections)
  • Mark Banister (CEO, Medipacs)
  • Pieter Muntendam (President and CEO, scPharmaceuticals)
  • Mindy Katz (Director of Product, Sorrel Medical)
  • Jesper Roested (CEO, Subcuject)
  • Graham Reynolds (VP and GM, Biologics, West Pharmaceutical Services)
  • Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  1. Over 50 large volume wearable injectors are either commercialized and/or are under development for delivery of a variety of drugs. Devices designed for administration of non-insulin drugs have high storage capacity and are being developed for delivery of high viscosity formulations. In fact, around 17% of such devices have the capability to hold 10-15ml of drug while 23% of the devices have a maximum storage capacity of more than 15 ml. Such devices are designed either for bolus dosing (40%), or continuous dosing (40%); there are certain products that have been designed to administer both continuous and bolus doses of drugs (20%).
  2. More than 10 drug-device combinations are currently developed/being evaluated for delivery of non-insulin drugs; of these, two drug-device combinations are already approved by the USFDA; these are Neulasta® (pegfilgrastim) OnPro™ Kit (Amgen / Insulet) and Pushtronex™ System (Amgen / West Pharmaceuticals). In addition, there are several other drug-device combinations that are being evaluated in clinical studies; examples include (in alphabetical order, no selection criteria) ND0701 (Neuroderm), scWear Infusor (SteadyMed Therapeutics) and Herceptin SC® Injector (Roche).
  3. Specifically for insulin delivery, close to 30 devices are being developed/approved. Of these, over 60% of the devices are already marketed. Examples include (in alphabetical order, no selection criteria) ACCU-CHEK® Combo System (Roche), MiniMed™ 630G Insulin Pump System (Medtronic), PAQ®, 3-Day Basal and Bolus Delivery (CeQur)and t: slim X2™ Insulin Pump (Tandem Diabetes Care). It is worth noting that specifically for the delivery of insulin, the market for large volume wearable injectors is anticipated to reach over USD 1.5 billion by 2030, representing a CAGR of close to 5%.
  4. The innovation in the field is primarily being driven by start-ups / small companies. Of all the companies developing large volume wearable injectors for non-insulin drugs, 50% are based in North America, primarily in the US. Examples of firms based in this region include (in alphabetical order, no selection criteria) Enable Injections, Medipacs, SteadyMed Therapeutics, scPharmaceuticals, and West Pharmaceutical Services. Examples of start-ups based in different geographical regions that have undertaken initiatives in this domain include (in alphabetical order, no selection criteria) Debiotech, Subcuject, ViCentra, Weibel CDS and Eoflow. In addition, a number of established companies are also making substantial contributions in this field; prominent players include (in alphabetical order, no selection criteria) 3M, Becton Dickinson, Insulet, West Pharmaceutical Services and Ypsomed.
  5. The development process of high-volume drug injector devices is complex due to the involvement of multiple components, which include both electrical and mechanical modules. Therefore, several device developers have opted to recruit the services of CMOs for manufacturing their proprietary drug delivery devices. Examples of companies that claim to provide manufacturing services to large volume drug delivery device developers include (in alphabetical order, no selection criteria) Baril Corporation, Daikyo Seiko, Flex International, Haselmeier, Phillips-Medisize, Vetter Pharma and Zollner.
  6. Close to 2,000 patents pertaining to the abovementioned devices have been filed till 2018. An analysis of these patents revealed that automated self-injection devices, with advanced features, are gradually gaining traction amongst patients with chronic disorders. Some of the advanced features integrated with the delivery devices include automatic reconstitution/priming mechanisms, provisions for audio and visual indications, error alerts and remote monitoring capability through connected devices. Examples of large volume wearable injectors that have been designed to be connected to smart devices include (in alphabetical order, no selection criteria) BD Libertas™ Wearable Injector (Becton Dickinson), Omnipod (Insulet), SmartDose® Generation I (West Pharmaceutical Services) and Subcuject Wearable Bolus Injection (Subcuject).
  7. An analysis of clinical studies that are being/have been conducted to evaluate the combinations of drugs and large volume wearable injectors reveal that close to 50% trials assessed the potential of using large volume wearable injectors for delivery of drugs intended for the treatment of neurological disorders. This is followed by the trials conducted to evaluate the effect of large volume wearable injectors in patients suffering from cardiovascular disorders (23%) and cancer (13%).
  8. Out of various marketed / under development drug molecules, close to 80 drugs demonstrated a relatively higher potential to be delivered via large volume wearable injectors and are most likely to be evaluated in different drug-device combinations in the near future. Of these, 90% are biologics and 10% are small molecules. These drugs (full list available in the main report) are designed for the treatment of chronic conditions, which require frequent dosing, and are not currently available in suitable self-administration systems.
  9. The market for large volume wearable devices for delivery of non-insulin drugs is expected to grow at an annualized rate of close to 40% between 2018 and 2030. It is worth noting that disposable injectors are anticipated to capture over 50% of the market share due to the safety concerns reported by the use of reusable injectors. Further, over 60% share of revenues is anticipated to be distributed between North America and Europe. However, we believe that certain counties in Asia Pacific are likely to grow at a faster rate as compared to other regions over the coming decade; this can be attributed to the increasing incidence of chronic disorders in these regions and a relatively less stringent regulatory environment. Specifically, neurological and oncological disorders are anticipated to capture a significantly higher market share in the future.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3M
  • Battelle
  • EG-GILERO
  • Innate Pharma
  • Neon Therapeutics
  • Sanofi
  • MORE

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Chapter Overview
3.2. An Overview of Drug Delivery Devices
3.3. Conventional Parenteral Delivery
3.3.1 Needlestick Injuries
3.3.1.1. Incidence and Cost Burden
3.3.1.2. Prevention of Needlestick Injuries
3.3.1.3. Government Legislations for the Prevention of Needlestick Injuries
3.4. Emergence of Self-Administration Devices
3.4.1. Driving Factors
3.4.1.1. Rising Burden of Chronic Diseases
3.4.1.2. Healthcare Cost Savings
3.4.1.3. Need for Immediate Treatment in Emergency Situations
3.4.1.4. Growing Injectable Drugs Market
3.4.1.5. Rising Focus on Patient Centricity
3.4.1.6. Need for Improving Medication Adherence
3.5. Available Self-Injection Devices
3.5.1. Prefilled Syringes
3.5.2. Pen-Injectors
3.5.3. Autoinjectors
3.5.4. Needle-Free Injectors
3.5.5. Large Volume Wearable Injectors
3.6. Regulatory Considerations
3.6.1. Medical Devices
3.6.2. Drug Device Combinations
3.7. Future Perspectives

4. Large Volume Wearable Injectors: Current Market Landscape
4.1. Chapter Overview
4.2. Large Volume Wearable Injectors: Overall Market Landscape
4.2.1. Large Volume Wearable Injectors for Non-Insulin Drugs: Market Landscape
4.2.1.1. Distribution by Stage of Development
4.2.1.2. Distribution by Type of Device
4.2.1.3. Distribution by Type of Dose
4.2.1.4. Distribution by Volume / Storage Capacity
4.2.1.5. Distribution by Usability
4.2.1.6. Distribution by Route of Administration
4.2.1.7. Distribution by Mode of Injection
4.2.1.8. Distribution by Mechanism of Action
4.2.2. Large Volume Drug Device Combinations: Market Landscape
4.2.2.1. Distribution by Stage of Development
4.2.2.2. Distribution by Type of Device
4.2.2.3. Distribution by Type of Dose
4.2.2.4. Distribution by Volume / Storage Capacity
4.2.2.5. Distribution by Usability
4.2.2.6. Distribution by Route of Administration
4.2.2.7. Distribution by Therapeutic Area
4.2.2.8. Distribution by Drug Compatibility
4.2.3. Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers (Devices and Drug Device Combinations)
4.2.3.1. Distribution by Geography
4.2.3.2. Distribution by Year of Establishment
4.2.3.3. Distribution by Company Size
4.2.4. Large Volume Wearable Injectors for Insulin: Market Landscape
4.2.4.1. Distribution by Stage of Development
4.2.4.2. Distribution by Type of Device
4.2.4.3. Distribution by Volume / Storage Capacity
4.2.4.4. Distribution by Usability
4.2.4.5. Distribution by Availability of Integrated CGM / BGM System
4.2.5. Large Volume Wearable Injectors for Insulin: Analysis of Developers
4.2.5.1. Distribution by Geography
4.2.5.2. Distribution by Year of Establishment
4.2.5.3. Distribution by Company Size

5. Product Competitiveness Analysis
5.1. Chapter Overview
5.2. Methodology
5.3. Product Competitiveness Analysis
5.3.1. Large Volume Wearable Injectors for Non-Insulin Drugs
5.3.2. Large Volume Drug Device Combinations
5.3.3. Large Volume Wearable Injectors for Insulin

6. Large Volume Wearable Injectors: Key Players
6.1. Chapter Overview
6.2. Large Volume Wearable Injectors for Non-Insulin Drugs: Key Players
6.2.1. Becton Dickinson
6.2.1.1. Company Snapshot
6.2.1.2. Product Portfolio
6.2.1.3. Financial Information
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Bespak
6.2.2.1. Company Snapshot
6.2.2.2. Product Portfolio
6.2.2.3. Financial Information
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Insulet
6.2.3.1. Company Snapshot
6.2.3.2. Product Portfolio
6.2.3.3. Financial Information
6.2.3.4. Recent Developments and Future Outlook
6.2.4. Medtronic
6.2.4.1. Company Snapshot
6.2.4.2. Product Portfolio
6.2.4.3. Financial Information
6.2.4.4. Recent Developments and Future Outlook
6.2.5. Roche
6.2.5.1. Company Snapshot
6.2.5.2. Product Portfolio
6.2.5.3. Financial Information
6.2.5.4. Recent Developments and Future Outlook
6.2.6. Sonceboz
6.2.6.1. Company Snapshot
6.2.6.2. Product Portfolio
6.2.6.3. Recent Developments and Future Outlook
6.2.7. Enable Injections
6.2.7.1. Company Snapshot
6.2.7.2. Product Portfolio
6.2.7.3. Recent Developments and Future Outlook
6.2.8. Sensile Medical
6.2.8.1. Company Snapshot
6.2.8.2. Product Portfolio
6.2.8.3. Recent Developments and Future Outlook
6.2.9. SteadyMed Therapeutics
6.2.9.1. Company Snapshot
6.2.9.2. Product Portfolio
6.2.9.3. Recent Developments and Future Outlook
6.2.10. West Pharmaceutical Services
6.2.10.1. Company Snapshot
6.2.10.2. Product Portfolio
6.2.10.3. Financial Information
6.2.10.4. Recent Developments and Future Outlook
6.2.11. Weibel CDS
6.2.11.1. Company Snapshot
6.2.11.2. Product Portfolio
6.2.11.3. Recent Developments and Future Outlook
6.3. Large Volume Wearable Injectors for Insulin: Key Players
6.3.1. CellNovo
6.3.1.1. Company Snapshot
6.3.1.2. Product Portfolio
6.3.1.3. Financial Information
6.3.1.4. Recent Developments and Future Outlook
6.3.2. CeQur
6.3.2.1. Company Snapshot
6.3.2.2. Product Portfolio
6.3.2.3. Recent Developments and Future Outlook
6.3.3. Debiotech
6.3.3.1. Company Snapshot
6.3.3.2. Product Portfolio
6.3.3.3. Recent Developments and Future Outlook
6.3.4. Eli Lilly
6.3.4.1. Company Snapshot
6.3.4.2. Product Portfolio
6.3.4.3. Financial Information
6.3.4.4. Recent Developments and Future Outlook
6.3.5. PharmaSens
6.3.5.1. Company Snapshot
6.3.5.2. Product Portfolio
6.3.5.3. Recent Developments and Future Outlook
6.3.6. SOOIL
6.3.6.1. Company Snapshot
6.3.6.2. Product Portfolio
6.3.6.3. Recent Developments and Future Outlook
6.3.7. Tandem Diabetes Care
6.3.7.1. Company Snapshot
6.3.7.2. Product Portfolio
6.3.7.3. Recent Developments and Future Outlook

7. Drug-Device Combinations: Tabulated Profiles
7.1. Chapter Overview
7.2. Apomorphine / ND0701
7.3. Bupivacaine / SMT-301
7.4. Ceftriaxone / sc2Wear® Infusor
7.5. Furosemide / sc2Wear® Infusor
7.6. Herceptin® / Single Use Injector
7.7. Ketorolac / SMT-201
7.8. Levadopa and Carbidopa / ND0612 and ND0901
7.9. Neulasta® / Omnipod®
7.10. Repatha® / Pushtronex® System
7.11. Treprostinil / Trevyent®

8. Patent Analysis
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Large Volume Wearable Injectors: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Patent Offices Involved
8.3.3. Analysis by CPC Classification
8.3.4. Emerging Areas
8.3.5. Leading Players Based on Number of Patents
8.4. Large Volume Wearable Injectors: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.4.2. Analysis by Geography
8.5. Large Volume Wearable Injectors: Patent Valuation Analysis

9. Emerging Trends On Social Media
9.1. Chapter Overview
9.2. Large Volume Wearable Injectors: Trends on Twitter
9.2.1. Historical Trend in Volume of Tweets
9.2.2. Trending Words / Phrases Related to Large Volume Wearable Injectors
9.2.3. Most Influential Authors
9.2.4. Popular Players on Twitter
9.2.4.1. Roche (Accu-Chek® Solo Micropump System)
9.2.4.2. Cellnovo (Cellnovo Insulin Pump)
9.2.4.3. Insulet (Omnipod®)
9.2.4.4. Medtronic (Minimed® Wearable Injectors)
9.2.4.5. Comparison of Popular Players Based on Number of Tweets
9.3. Concluding Remarks

10. Clinical Trial Analysis
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Large Volume Wearable Injectors: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Phase
10.3.4. Analysis by Study Design
10.3.5. Analysis by Target Therapeutic Area
10.3.6. Analysis by Clinical Endpoints
10.3.7. Analysis by Study Focus

11. Case Study: Role of CMOS in Device Development Supply Chain
11.1. Chapter Overview
11.2. Device Development Supply Chain
11.3. Significance of CMOs in the Drug Delivery Device Development Process
11.4. List of Contract Manufacturing Organizations
11.4.1. Contract Manufacturers: Geographical Distribution and Services Offered

12. Large Volume Wearable Injectors: Likely Drug Candidates
12.1. Chapter Overview
12.2. Marketed Drugs
12.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
12.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
12.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
12.2.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors
12.3. Clinical Drug Candidates
12.3.1. Biologics
12.3.1.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
12.3.1.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
12.3.1.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
12.3.1.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors
12.3.2. Small Molecules
12.3.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
12.3.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
12.3.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
12.3.2.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors

13. Market Sizing and Opportunity Analysis
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2018-2030 (By Value)
13.3.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2018-2030 (By Value)
13.3.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2018-2030 (By Value)
13.3.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2018-2030 (By Value)
13.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2018-2030 (By Value)
13.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2018-2030 (By Value)
13.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2018-2030 (By Value)
13.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2018-2030 (By Value)
13.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2018-2030 (By Value)
13.5.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2018-2030 (By Value)
13.5.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2018-2030 (By Value)
13.5.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2018-2030 (By Value)
13.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2018-2030 (By Value)
13.6.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2018-2030 (By Value)
13.6.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
13.6.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2018-2030 (By Value)
13.7. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2018-2030 (By Volume)
13.7.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2018-2030 (By Volume)
13.7.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2018-2030 (By Volume)
13.7.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2018-2030 (By Volume)
13.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2018-2030 (By Volume)
13.8.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2018-2030 (By Volume)
13.8.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2018-2030 (By Volume)
13.8.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2018-2030 (By Volume)
13.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2018-2030 (By Volume)
13.9.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2018-2030 (By Volume)
13.9.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2018-2030 (By Volume)
13.9.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2018-2030 (By Volume)
13.10. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2018-2030 (By Value)
13.10.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2018-2030 (By Value)
13.10.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2018-2030 (By Value)
13.10.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2018-2030 (By Value)
13.11. Global Large Volume Wearable Injectors Market for Insulin, 2018-2030
13.11.1. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2018-2030
13.11.2. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2018-2030
13.12. Large Volume Wearable Injectors Market for Insulin in North America, 2018-2030
13.12.1. Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2018-2030
13.12.2. Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2018-2030
13.13. Large Volume Wearable Injectors Market for Insulin in Europe, 2018-2030
13.13.1. Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2018-2030
13.13.2. Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2018-2030
13.14. Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2018-2030
13.14.1. Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2018-2030
13.14.2. Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2018-2030

14. Future Growth Opportunities
14.1. Chapter Overview
14.2. SWOT Analysis
14.2.1. Strengths
14.2.2. Weaknesses
14.2.3. Opportunities
14.2.4. Threats
14.3. Future Growth Opportunities

15. Executive Insights
15.1. Chapter Overview
15.2. Elcam Medical
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist
15.3. Enable Injections
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Michael Hooven, President and Chief Executive Officer
15.4. Medipacs
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Mark Banister, Chief Executive Officer
15.5. Ratio Drug Delivery
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Ben Moga, President
15.6. scPharmaceuticals
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Pieter Muntendam, President and Chief Executive Officer
15.7. Sorrel Medical
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Mindy Katz, Director of Product
15.8. Subcuject
15.8.1. Company Snapshot
15.8.2. Interview Transcript: Jesper Roested, Chief Executive Officer
15.9. West Pharmaceutical Services
15.9.1. Company Snapshot
15.9.2. Interview Transcript: Graham Reynolds, Vice President and General Manager, Biologics and Tiffany H. Burke, Director, Global Communications

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

List of Figures:
Figure 3.1 Popular Drug Delivery Systems
Figure 3.2 Types of Self-Injection Devices
Figure 3.3 Evolution of Healthcare Safety Legislations
Figure 3.4 Components of a Large Volume Wearable Injector
Figure 4.1 Large Volume Wearable Injectors: Overall Market Landscape
Figure 4.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Stage of Development
Figure 4.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Figure 4.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Figure 4.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Volume / Storage Capacity
Figure 4.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Figure 4.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route of Administration
Figure 4.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Figure 4.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mechanism of Action
Figure 4.10 Large Volume Drug Device Combinations: Distribution by Stage of Development
Figure 4.11 Large Volume Drug Device Combinations: Distribution by Type of Device
Figure 4.12 Large Volume Drug Device Combinations: Distribution by Type of Dose
Figure 4.13 Large Volume Drug Device Combinations: Distribution by Volume / Storage Capacity
Figure 4.14 Large Volume Drug Device Combinations: Distribution by Usability
Figure 4.15 Large Volume Drug Device Combinations: Distribution by Route of Administration
Figure 4.16 Large Volume Drug Device Combinations: Distribution by Therapeutic Area
Figure 4.17 Large Volume Drug Device Combinations: Distribution by Drug Compatibility
Figure 4.18 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Geography (Devices and Drug Device Combinations)
Figure 4.19 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Year of Establishment (Devices and Drug Device Combinations)
Figure 4.20 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Size (Devices and Drug Device Combinations)
Figure 4.21 Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
Figure 4.22 Large Volume Wearable Injectors for Insulin: Distribution by Type of Device
Figure 4.23 Large Volume Wearable Injectors for Insulin: Distribution by Volume / Storage Capacity
Figure 4.24 Large Volume Wearable Injectors for Insulin: Distribution by Usability
Figure 4.25 Large Volume Wearable Injectors for Insulin: Distribution by Availability of Integrated CGM / BGM Systems
Figure 4.26 Large Volume Wearable Injectors for Insulin: Distribution of Developers by Geographical Location
Figure 4.27 Large Volume Wearable Injectors for Insulin: Distribution of Developers by Year of Establishment
Figure 4.28 Large Volume Wearable Injectors for Insulin: Distribution of Developers by Size
Figure 4.29 Large Volume Wearable Injectors: Market Landscape Summary
Figure 5.1 Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 5.2 Product Competitiveness Analysis: Large Volume Drug Device Combinations
Figure 5.3 Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin
Figure 8.1 Patent Portfolio: Distribution by Type of Patent
Figure 8.2 Patent Portfolio: Cumulative Distribution by Publication Year, Pre-2005-2018
Figure 8.3 Patent Portfolio: Distribution by Patent Offices Involved
Figure 8.4 Patent Portfolio: Distribution by CPC Classification
Figure 8.5 Patent Portfolio: Emerging Areas
Figure 8.6 Patent Portfolio: Leading Players
Figure 8.7 Patent Portfolio (Industry Players): Benchmarking by Patent Characteristics
Figure 8.8 Patent Portfolio (Industry Players): Benchmarking by Number of Patents across Different Geographies
Figure 8.9 Patent Portfolio: Benchmarking by International Patents
Figure 8.10 Patent Portfolio: Distribution of Patents by Age (1985-July 2018)
Figure 8.11 Patent Portfolio: Valuation Analysis
Figure 9.1 Social Media Analysis: Historical Trend on Twitter, 2013-2018
Figure 9.2 Social Media Analysis: Trending Words / Phrases on Twitter
Figure 9.3 Social Media Analysis: Most Influential Authors related to Large Volume Wearable Injectors on Twitter
Figure 9.4 Social Media Analysis: Popular Players (Roche)
Figure 9.5 Social Media Analysis: Popular Players (CellNovo)
Figure 9.6 Social Media Analysis: Popular Players (Insulet)
Figure 9.7 Social Media Analysis: Popular Players (Medtronic)
Figure 9.8 Social Media Analysis: Comparison of Popular Players on Twitter
Figure 10.1 Clinical Trial Analysis: Cumulative Distribution of Number of Trials by Start Year, Pre-2010-2018
Figure 10.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.4 Clinical Trial Analysis: Distribution by Study Design
Figure 10.5 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 10.6 Clinical Trial Analysis: Distribution by Clinical Outcomes
Figure 10.7 Clinical Trial Analysis: Study Focus
Figure 11.1 CMOs for Large Volume Wearable Injectors: Market Landscape and Services Offered
Figure 12.1 Marketed / Pipeline Drug Candidates: Parameters and Scoring Criteria for Likely Drug Candidates Analysis
Figure 13.1 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Base Case, 2018-2030 (USD Million)
Figure 13.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2018-2030 (USD Million)
Figure 13.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2018-2030 (USD Million)
Figure 13.4 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2018-2030 (USD Million)
Figure 13.5 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2018-2030 (USD Million)
Figure 13.6 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2018-2030 (USD Million)
Figure 13.7 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 13.8 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2018-2030 (USD Million)
Figure 13.9 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2018-2030 (USD Million)
Figure 13.10 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2018-2030 (USD Million)
Figure 13.11 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 13.12 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2018-2030 (USD Million)
Figure 13.13 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2018-2030 (USD Million)
Figure 13.14 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2018-2030 (USD Million)
Figure 13.15 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Figure 13.16 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2018-2030 (USD Million)
Figure 13.17 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Base Case, 2018-2030 (Units, Million)
Figure 13.18 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2018-2030 (Units, Million)
Figure 13.19 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2018-2030 (Units, Million)
Figure 13.20 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2018-2030 (Units, Million)
Figure 13.21 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2018-2030 (Units, Million)
Figure 13.22 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2018-2030 (Units, Million)
Figure 13.23 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2018-2030 (Units, Million)
Figure 13.24 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2018-2030 (Units, Million)
Figure 13.25 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2018-2030 (Units, Million)
Figure 13.26 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2018-2030 (Units, Million)
Figure 13.27 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Figure 13.28 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2018-2030 (Units, Million)
Figure 13.29 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2018-2030 (Units, Million)
Figure 13.30 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2018-2030 (Units, Million)
Figure 13.31 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Figure 13.32 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2018-2030 (Units, Million)
Figure 13.33 Global Large Volume Wearable Injectors Market for Insulin, Base Case, 2018-2030 (USD Million)
Figure 13.34 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2018-2030 (USD Million)
Figure 13.35 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2018-2030 (USD Million)
Figure 13.36 Large Volume Wearable Injectors Market for Insulin in North America, 2018-2030 (USD Million)
Figure 13.37 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2018-2030 (USD Million)
Figure 13.38 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2018-2030 (USD Million)
Figure 13.39 Large Volume Wearable Injectors Market for Insulin in Europe, 2018-2030 (USD Million)
Figure 13.40 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2018-2030 (USD Million)
Figure 13.41 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2018-2030 (USD Million)
Figure 13.42 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2018-2030 (USD Million)
Figure 13.43 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2018-2030 (USD Million)
Figure 13.44 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)

List of Tables
Table 3.1 List of Prefilled Syringes
Table 3.2 List of Pen-Injector Systems
Table 3.3 List of Autoinjector Systems
Table 3.4 List of Needle-Free Injectors
Table 4.1 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Development Status and Device Features
Table 4.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Administration Related Parameters
Table 4.3 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Development Status and Device Features
Table 4.4 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Administration Related Parameters
Table 4.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Developers (Both Devices and Drug Device Combinations)
Table 4.6 Large Volume Wearable Injectors for Insulin: Information on Development Status and Device Features
Table 4.7 Large Volume Wearable Injectors for Insulin: Information on Developers
Table 6.1 Large Volume Wearable Injectors for Non-Insulin Drugs: List of Players Profiled
Table 6.2 Large Volume Wearable Injectors for Insulin: List of Players Profiled
Table 7.1 Large Volume Wearable Injectors: List of Drugs Approved / Under Evaluation
Table 7.2 Tabulated Profile: Apomorphine / ND0701
Table 7.3 Tabulated Profile: Bupivacaine / SMT-301
Table 7.4 Tabulated Profile: Ceftriaxone / sc2Wear® Infusor
Table 7.5 Tabulated Profile: Furosemide / sc2Wear® Infusor
Table 7.6 Tabulated Profile: Herceptin® / Single Use Injector
Table 7.7 Tabulated Profile: Ketorolac / SMT-201
Table 7.8 Tabulated Profile: Levadopa and Carbidopa / ND0612 and ND0901
Table 7.9 Tabulated Profile: Neulasta® / Omnipod®
Table 7.10 Tabulated Profile: Repatha® / Pushtronex® System
Table 7.11 Tabulated Profile: Treprostinil / Trevyent®
Table 8.1 Patent Portfolio: Most Popular CPC Symbols
Table 8.2 Patent Portfolio: List of Top CPC Classifications
Table 8.3 Patent Portfolio: Summary of Benchmarking Analysis
Table 8.4 Patent Portfolio: Categorization based on Proprietary Scoring Criteria
Table 8.5 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 11.1 List of Contract Manufacturing Organizations
Table 12.1 Marketed Molecules: Most Likely Candidates for Delivery via Large Volume  Wearable Injectors
Table 12.2 Marketed Molecules: Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 12.3 Marketed Molecules: Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 12.4 Marketed Molecules: Unlikely Candidates for Delivery via Large Volume Wearable Injectors
Table 12.5 Clinical Drug Candidates (Biologics): Most Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 12.6 Clinical Drug Candidates (Biologics): Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 12.7 Clinical Drug Candidates (Biologics): Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 12.8 Clinical Drug Candidates (Biologics): Unlikely Candidates for Delivery via Large Volume Wearable Injectors
Table 12.9 Clinical Drug Candidates (Small Molecules): Most Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 12.10 Clinical Drug Candidates (Small Molecules): Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 12.11 Clinical Drug Candidates (Small Molecules): Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 12.12 Clinical Drug Candidates (Small Molecules): Unlikely Candidates for Delivery via Large Volume Wearable Injectors
Table 13.1 Large Volume Drug Device Combinations: List of Approved / Under Development Products
Table 15.1 Company Snapshot: Elcam Medical
Table 15.2 Company Snapshot: Enable Injections
Table 15.3 Company Snapshot: Medipacs
Table 15.4 Company Snapshot: Ratio Drug Delivery
Table 15.5 Company Snapshot: scPharmaceuticals
Table 15.6 Company Snapshot: Sorrel Medical
Table 15.7 Company Snapshot: Subcuject
Table 15.8 Company Snapshot: West Pharmaceutical Services
Table 16.1 Large Volume Wearable Injectors: Overall Market Landscape
Table 16.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Stage of Development
Table 16.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Table 16.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Table 16.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Volume / Storage Capacity
Table 16.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Table 16.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route of Administration
Table 16.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Table 16.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mechanism of Action
Table 16.10 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Stage of Development
Table 16.11 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Device
Table 16.12 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Dose
Table 16.13 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Volume / Storage Capacity
Table 16.14 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Usability
Table 16.15 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Therapeutic Area
Table 16.16 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Route of Administration
Table 16.17 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Drug Compatibility
Table 16.18 Large Volume Wearable Injectors for Insulin and Non-Insulin Drugs: Distribution of Developers by Geography (Both Devices and Drug Device Combinations)
Table 16.19 Large Volume Wearable Injectors for Insulin and Non-Insulin Drugs: Distribution of Developers by Year of Establishment (Both Devices and Drug Device Combinations)
Table 16.20 Large Volume Wearable Injectors for Insulin and Non-Insulin Drugs: Distribution of Developers by Size (Both Devices and Drug Device Combinations)
Table 16.21 Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
Table 16.22 Large Volume Wearable Injectors for Insulin: Distribution by Type of Device
Table 16.23 Large Volume Wearable Injectors for Insulin: Distribution by Volume / Storage Capacity
Table 16.24 Large Volume Wearable Injectors for Insulin: Distribution by Usability
Table 16.25 Large Volume Wearable Injectors for Insulin: Distribution by Availability of Integrated CGM / BGM Systems
Table 16.26 Large Volume Wearable Injectors for Insulin: Distribution of Developers by Geography
Table 16.27 Large Volume Wearable Injectors for Insulin: Distribution of Developers by Year of Establishment
Table 16.28 Large Volume Wearable Injectors for Insulin: Distribution of Developers by Size
Table 16.29 Large Volume Wearable Injectors: Market Landscape Summary
Table 16.30 Patent Portfolio: Distribution by Type of Patent
Table 16.31 Patent Portfolio: Cumulative Distribution by Publication Year, Pre-2005-2018
Table 16.32 Patent Portfolio: Distribution by Patent Offices Involved
Table 16.33 Patent Portfolio: Leading Players
Table 16.34 Patent Portfolio (Industry Players): Benchmarking by Number of Patents across Different Geographies
Table 16.35 Patent Portfolio: Benchmarking by International Patents
Table 16.36 Patent Portfolio: Distribution of Patents by Age (1985-July 2018)
Table 16.37 Patent Portfolio: Valuation Analysis
Table 16.38 Social Media Analysis: Comparison of Popular Players on Twitter
Table 16.39 Clinical Trial Analysis: Cumulative Distribution of Number of Trials by Start Year, Pre-2010-2018
Table 16.40 Clinical Trial Analysis: Distribution by Trial Status
Table 16.41 Clinical Trial Analysis: Distribution by Trial Phase
Table 16.42 Clinical Trial Analysis: Distribution by Study Design
Table 16.43 Clinical Trial Analysis: Distribution by Target Therapeutic Area / Indication
Table 16.44 Clinical Trial Analysis: Distribution by Clinical Outcomes
Table 16.45 Clinical Trial Analysis: Study Focus
Table 16.46 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenario, 2018-2030 (USD Million)
Table 16.47 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2018-2030 (USD Million)
Table 16.48 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2018-2030 (USD Million)
Table 16.49 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2018-2030 (USD Million)
Table 16.50 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2018-2030 (USD Million)
Table 16.51 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2018-2030 (USD Million)
Table 16.52 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 16.53 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2018-2030 (USD Million)
Table 16.54 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2018-2030 (USD Million)
Table 16.55 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2018-2030 (USD Million)
Table 16.56 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 16.57 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2018-2030 (USD Million)
Table 16.58 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2018-2030 (USD Million)
Table 16.59 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2018-2030 (USD Million)
Table 16.60 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)
Table 16.61 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2018-2030 (USD Million)
Table 16.62 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Cases, 2018-2030 (Units, Million)
Table 16.63 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2018-2030 (Units, Million)
Table 16.64 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2018-2030 (Units, Million)
Table 16.65 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2018-2030 (Units, Million)
Table 16.66 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2018-2030 (Units, Million)
Table 16.67 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2018-2030 (Units, Million)
Table 16.68 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2018-2030 (Units, Million)
Table 16.69 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2018-2030 (Units, Million)
Table 16.70 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2018-2030 (Units, Million)
Table 16.71 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2018-2030 (Units, Million)
Table 16.72 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2018-2030 (Units, Million)
Table 16.73 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2018-2030 (Units, Million)
Table 16.74 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2018-2030 (Units, Million)
Table 16.75 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2018-2030 (Units, Million)
Table 16.76 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2018-2030 (Units, Million)
Table 16.77 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2018-2030 (Units, Million)
Table 16.78 Global Large Volume Wearable Injectors Market for Insulin, Conservative, Base and Optimistic Cases, 2018-2030 (USD Million)
Table 16.79 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2018-2030 (USD Million)
Table 16.80 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2018-2030 (USD Million)
Table 16.81 Large Volume Wearable Injectors Market for Insulin in North America, 2018-2030 (USD Million)
Table 16.82 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2018-2030 (USD Million)
Table 16.83 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2018-2030 (USD Million)
Table 16.84 Large Volume Wearable Injectors Market for Insulin in Europe, 2018-2030 (USD Million)
Table 16.85 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2018-2030 (USD Million)
Table 16.86 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2018-2030 (USD Million)
Table 16.87 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2018-2030 (USD Million)
Table 16.88 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2018-2030 (USD Million)
Table 16.89 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2018-2030 (USD Million)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 3M
  • Battelle
  • EG-GILERO
  • Innate Pharma
  • Neon Therapeutics
  • Sanofi
  • MORE

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the large volume wearable injectors market in the short-mid term and long term.

Chapter 3 provides a general introduction to large volume wearable injectors, highlighting the growing demand for medical devices that enable self-administration. The chapter lays emphasis on the need for such devices, in terms of the rising incidence and prevalence of chronic diseases. Subsequently, it provides an overview of the different types of self-injection devices available in the market, listing their various advantages. It also features a brief discussion of the concerns related to the use of such devices.

Chapter 4 presents separate lists, highlighting large volume wearable injectors capable of delivering any suitable drug and drug-device combinations designed for delivery of specific drugs, respectively. In addition, the chapter includes a detailed analysis of these lists based on the products’ status of development, type of device, type of dose, route of administration, usability, mechanism of action, mode of injection, the maximum volume of the device and availability of the connected mobile application. In addition, the chapter lists the large volume wearable injectors for delivery of insulin, highlighting the aforementioned parameters for each of them and information on the provision of CGM \ BGM systems.

Chapter 5 presents a product competitiveness analysis of all large volume wearable injectors based on the supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 6 provides detailed profiles of key large volume wearable injectors manufacturers. Each profile presents a brief overview of the company, financial information (if available), product portfolio, recent developments, and a comprehensive future outlook.

Chapter 7 provides tabulated profiles of drug-device combination products and each profile include drug specifications, mechanism of action, development history, the current status of development, and dosage and sales information.

Chapter 8 provides an in-depth patent analysis, presenting an overview on the filed/granted patents related to wearable injectors for the delivery of drugs in large volumes. For this analysis, we looked at the patents that have been published by various players since 1984. The analysis highlights the key information and trends associated with these patents, including patent type (granted patents, patent applications and others), patent publication year, patent offices (USPTO, WIPO, APO, EPO and others), CPC classification, emerging areas, and the leading industry players. The chapter also includes a patent benchmarking analysis and patent valuation analysis.

Chapter 9 provides insights into the popularity of large volume wearable injectors on the social media platform, Twitter. The chapter highlights the yearly distribution of tweets posted on the platform in the period between January 2013 and September 2018, and the most significant events responsible for the increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords/phrases and social media activity of the most popular players with the comparison of the tweets associated with their product. It also presents a bubble analysis of the most influential authors related to large volume wearable injectors on Twitter.

Chapter 10 presents a comprehensive clinical trial analysis of the complete and active studies being conducted to evaluate the combinations of drugs and large volume wearable injectors. For the purpose of this analysis, we looked at the clinical studies for these devices which started in 2010 and analyzed them on the basis of various parameters, such as trial start year, current trail status, current trial phase, study design, targeted therapeutic area, study focus, and clinical outcomes.

Chapter 11 includes a brief case study on the role of contract manufacturing organizations in the overall manufacturing process/supply chain of a wearable injector. It includes a short description of the manufacturing services provided by these organizations in the making of device components (primary containers), infusion sets, adhesives, closures, and injection moldings. In addition, it presents a world map highlighting the location of the CMOs and their device manufacturing service portfolio.

Chapter 12 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via large volume wearable injectors in the future. It is worth highlighting that this list was compiled based on various parameters, such as route of administration, target therapeutic indication and the current dosage regimen of the aforementioned product candidates. For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous/intramuscular/ intravenous). Additionally, we reviewed over 1,400 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via a large volume wearable injector in the future was estimated using the weighted average method.

Chapter 13 presents a comprehensive market forecast analysis, highlighting the future potential of large volume wearable injectors, till the year 2030. We have segregated the opportunity on the basis of the therapeutic area, geographical distribution of the market (North America / Europe / Asia Pacific / RoW), type of device (patch pump/injector and infusion pump/injector) and usability (reusable/disposable). In addition, the chapter features an opportunity analysis of the of the large volume wearable injectors for delivery of insulin.

Chapter 14 presents a detailed discussion on the future opportunities of wearable injectors for large volume drug delivery. It also highlights the key parameters and trends that are likely to influence the future of this market, under a comprehensive SWOT framework.

Chapter 15 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with (in alphabetical order of company name) Menachem Zucker (VP and Chief Scientist, Elcam Medical), Michael Hooven (CEO, Enable Injections), Mark Banister (CEO, Medipacs), Pieter Muntendam (President and CEO, scPharmaceuticals), Mindy Katz (Director of Product, Sorrel Medical), Jesper Roested (CEO, Subcuject), Graham Reynolds (VP and GM, Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services).

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which contains a list of companies and organizations mentioned in this report.

Note: Product cover images may vary from those shown
5 of 5
  • 3M
  • Abbott
  • AbbVie
  • AbGenomics
  • Ablynx
  • Acceleron Pharma
  • Actavis Pharma
  • ADC Therapeutics
  • Adrenomed
  • Aduro BioTech
  • Advaxis
  • Aeglea BioTherapeutics
  • Affibody
  • Affimed
  • Agenus
  • AgonOx
  • Akesobio Australia
  • Alder BioPharmaceuticals
  • Alector
  • Alexion Pharmaceuticals
  • Alkahest
  • Alkermes
  • Allakos
  • Allergan
  • Allozyne
  • Alnylam Pharmaceuticals
  • AlphaCore Pharma
  • Altor BioScience
  • Ambrx
  • amcure
  • Amgen
  • Amicus Therapeutics
  • Amphivena Therapeutics
  • Amplyx Pharmaceuticals
  • Amylin Pharmaceuticals
  • Angiochem
  • Animas
  • Antares Pharma
  • Antaros Medical
  • Aprea Therapeutics
  • Aptevo Therapeutics
  • argenx
  • Argos Therapeutics
  • ArmaGen
  • ARMO BioSciences
  • Aronora
  • Asklepion Pharmaceuticals
  • Astellas Pharma
  • AstraZeneca
  • Atridia
  • AVEO Pharmaceuticals
  • Axon Neuroscience
  • Bang & Olufsen Medicom
  • Baril
  • Basilea Pharmaceutica
  • Battelle
  • Baxter International
  • Bayer
  • Bayhill Therapeutics
  • Becton Dickinson
  • BeiGene
  • Beijing Dongfang Biotech
  • Bespak
  • Bio-Path Holdings
  • Bio-Thera Solutions
  • BioArctic
  • BIOCAD
  • bioCSL
  • Biogen
  • BioIntegrator
  • Bioject Medical Technologies
  • BioMarin Pharmaceutical
  • Bioniz Therapeutics
  • BioNTech
  • Biotest Pharmaceuticals
  • Boehringer Ingelheim
  • Boston Pharmaceuticals
  • Bristol Myers Squibb
  • Calando Pharmaceuticals
  • Calibra Medical
  • CANbridge Life Sciences
  • Cancer Advances
  • Cara Therapeutics
  • Catalyst Biosciences
  • CEL-SCI
  • Celgene
  • Celldex Therapeutics
  • Cellnovo
  • CeQur
  • Chimerix
  • CHO Pharma
  • Chugai Pharmaceutical
  • Cidara Therapeutics
  • Cleveland BioLabs
  • Conjupro Biotherapeutics
  • ContraFect
  • Cour Pharmaceutical Development
  • CSL Behring
  • CSPC Pharmaceutical Group
  • CStone Pharmaceuticals
  • CureTech
  • CytoDyn
  • Daikyo Seiko
  • Datwyler
  • Debiotech
  • DEKA
  • Dekkun
  • Delta-Fly Pharma
  • Dendreon
  • Dexcom
  • DiaMedica Therapeutics
  • Diamyd Medical
  • E3D Elcam Drug Delivery Devices
  • EG-GILERO
  • Eisai
  • Eli Lilly
  • Elusys Therapeutics
  • EMD Serono
  • Emergent BioSolutions
  • Enable Injections
  • Endo Pharmaceuticals
  • Endocyte
  • EnGeneIC
  • EOFlow
  • EpicentRx
  • Eternity Healthcare
  • European Pharma Group
  • F2G
  • Fabrico
  • FibroGen
  • Finox Biotech
  • Five Prime Therapeutics
  • Flex Pharma
  • Flowonix Medical
  • Galaxy Biotech
  • Galena Biopharma
  • Genentech
  • GENERON
  • GeneScience Pharmaceuticals
  • Genexine
  • Genzyme
  • Gerresheimer
  • Gilead Sciences
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Gliknik
  • Guangzhou Cellprotek Pharmaceutical
  • HAL Allergy
  • Halozyme Therapeutics
  • Hanmi Pharmaceutical
  • Haselmeier
  • Helsinn Healthcare
  • Hemispherx Biopharm
  • Hoffmann-La Roche
  • Huabo Biopharm
  • ImClone Systems
  • Immatics Biotechnologies
  • Immune Response BioPharma
  • ImmuneMed
  • ImmunGene
  • Immunocore
  • ImmunoFrontier
  • ImmunoGen
  • Immunomedics
  • Immunotope
  • Immunovaccine
  • Implicit Bioscience
  • Incuron
  • Incyte
  • Injex Pharma
  • Innate Pharma
  • Innovent Biologics
  • Inovio Pharmaceuticals
  • Insulet
  • iNtRON Biotechnology
  • IO Biotech
  • Ionis Pharmaceuticals
  • Ipsen
  • ISU ABXIS
  • Janssen
  • Jerini
  • JHL Biotech
  • Jiangsu Hengrui Medicine
  • Jiangsu T-Mab Biopharma
  • Johnson & Johnson
  • Jounce Therapeutics
  • kaleo
  • KaloBios Pharmaceuticals
  • Kiniksa Pharmaceuticals
  • Kissei Pharmaceutical
  • Kura Oncology
  • Kyowa Hakko Kirin
  • Labrys Biologics
  • Leadiant Biosciences
  • LEO Pharma
  • Levicept
  • Life Science Pharmaceuticals
  • MabVax Therapeutics
  • MacroGenics
  • Medical International Technology
  • MedImmune
  • Medipacs
  • MedPro Safety Products
  • Medtronic
  • Medtrum Technologies
  • Menarini Group
  • Merck
  • Merck Sharp & Dohme
  • Mereo BioPharma
  • Meridian Medical Technologies
  • Merrimack Pharmaceuticals
  • Mersana Therapeutics
  • Merus
  • Merz Pharma
  • Millennium Pharmaceuticals
  • MiNA Therapeutics
  • miRagen Therapeutics
  • Mitsubishi Tanabe Pharma
  • Moderna Therapeutics
  • Molecular Partners
  • Molecular Templates
  • MolMed
  • MorphoSys
  • Morphotek
  • MTD Micro Molding
  • Mylan
  • NantBioScience
  • Naurex
  • Navidea Biopharmaceuticals
  • Neogenix Oncology
  • Neon Therapeutics
  • NeuroDerm
  • Nordic Bioscience
  • Northern Biologics
  • Novartis Pharmaceuticals
  • Novimmune
  • NOVO Engineering
  • Novo Nordisk
  • OBI Pharma
  • Octapharma
  • Omeros
  • Oncology Venture
  • OncoMed Pharmaceuticals
  • OncoPep
  • Oncopeptides
  • Oncternal Therapeutics
  • Oncurious
  • Opthea
  • Optimer Pharmaceuticals
  • OSE Immunotherapeutics
  • Otsuka Pharmaceutical
  • Paion UK
  • Pfizer
  • PharmaJet
  • PharmaMar
  • PharmaSens
  • PhaseBio Pharmaceuticals
  • Phillips-Medisize
  • Philogen
  • Phosplatin Therapeutics
  • Pierre Fabre
  • Pique Therapeutics
  • Polaris Group
  • Polyphor
  • Prescient Therapeutics
  • Prestige BioPharma
  • Promedior
  • Prometheus Laboratories
  • Protalix Biotherapeutics
  • Proven Process Medical Devices
  • Quest PharmaTech
  • Quintessence Biosciences
  • R-Pharm
  • Ratio Drug Delivery
  • RAUMEDIC
  • Recro Pharma
  • Regeneron Pharmaceuticals
  • REMD Biotherapeutics
  • Resolve Therapeutics
  • rEVO Biologics
  • Rhythm Pharmaceuticals
  • Roche
  • Roehr pharmaceuticals
  • Sagentia
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Santarus
  • Savient Pharmaceuticals
  • scPharmaceuticals
  • Seattle Genetics
  • Selecta Biosciences
  • Selexys Pharmaceuticals
  • Sensile Medical
  • Serina Therapeutics
  • Shire
  • SMC Global
  • Smiths Medical
  • Sonceboz
  • SOOIL
  • SteadyMed Therapeutics
  • Stealth BioTherapeutics
  • Stemline Therapeutics
  • Stevanato Group
  • Subcuject
  • Sumitomo Dainippon Pharma
  • Sunovion Pharmaceuticals
  • SymBio Pharmaceuticals
  • Symphogen
  • Synectics
  • Synermore Biologics
  • Syntimmune
  • Syros Pharmaceuticals
  • TaiMed Biologics
  • Taiwan Liposome Company
  • Takeda Pharmaceutical
  • Tandem Diabetes Care
  • Tanvex BioPharma
  • Tarveda Therapeutics
  • Teva Pharmaceutical
  • TG Therapeutics
  • Tolero Pharmaceuticals
  • TRACON Pharmaceuticals
  • Translational Sciences
  • Turnstone Biologics
  • United BioPharma
  • Vaccinex
  • Vaccinogen
  • Valtronic
  • vasopharm BIOTECH
  • Verily Life Sciences
  • Vetter Pharma
  • ViCentra
  • Viela Bio
  • ViiV Healthcare
  • Visterra
  • Vitaeris
  • Vivozon
  • Weibel CDS
  • West Pharmaceutical Services
  • Wockhardt
  • Xbiotech
  • Xencor
  • XOMA
  • Ypsomed
  • Zafgen
  • Zollner
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll